Global Vasculitis Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight

2022年04月08日01:00

Vasculitis Pipeline constitutes 30+ key companies continuously working towards developing 30+ Vasculitis treatment therapies, analyzes DelveInsight

Las Vegas, USA, April 07, 2022 (GLOBE NEWSWIRE) -- Global Vasculitis Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight

Vasculitis Pipeline constitutes 30+ key companies continuously working towards developing 30+ Vasculitis treatment therapies, analyzes DelveInsight

DelveInsight’s ‘Vasculitis Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Vasculitis pipeline domain.

Some of the essential takeaways from the Vasculitis Pipeline report:

  • DelveInsight’s Vasculitis Pipeline analysis depicts 30+ active players proactively working to develop 30+ pipeline treatment therapies.
  • Some of the key Dengue companies working to develop potential drug candidates to improve the Vasculitis treatment scenario include CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and many others.
  • Essential Vasculitis pipeline therapies such as AMB 301, Research, program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others are under development in different phases of clinical studies.
  • In October 2021, Novartis Pharmaceuticals initiated a randomized, parallel-group, double-blind, placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of Secukinumab 300 mg administered subcutaneously versus placebo, in combination with glucocorticoid taper regimen, in patients With Giant Cell Arteritis (GCA)
  • Chemocentryx has launched TAVNEOS in the fourth quarter of 2021 following FDA approval on October 8, 2021, as an adjunctive treatment in adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis, in combination with standard therapy including glucocorticoids.
  • ChemoCentryx received approval from European Union (EU) for its drug, Tavneos (avacopan), to treat adult patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis) in January 2022.
  • In November 2021, InflaRx reported positive data from the European Phase II IXCHANGE study of vilobelimab, a first-in-class anti-C5a antibody, in patients with ANCA-associated vasculitis (AAV). The study achieved its principal objective, demonstrating comparable clinical response of vilobelimab to the standard of care, while significantly reducing the need for glucocorticoid (GC) treatment.
  • In November 2021, U.S. FDA’s Office For Orphan Products Development (OOPD) granted the orphan drug status for Ambulero’s gene therapy candidate, AMB-301, to treat Buerger’s Disease (BD), also known as Thromboangiitis Obliterans (TAO).
  • Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated in Phase III clinical trial to treat Giant Cell Arteritis.
  • Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate in the Phase II stage of development.

Request a sample and discover more about the scope of the report offerings @ Vasculitis Novel & Upcoming Drugs

The Vasculitis pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Vasculitis products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Vasculitis pipeline landscape.

Vasculitis Overview

Vasculitis involves inflammation of the blood vessels. The inflammation can cause the walls of the blood vessels to thicken, which reduces the width of the passageway through the vessel. If blood flow is restricted, it can result in organ and tissue damage. Vasculitis can affect people at any age. Some forms affect blood vessels that go to or supply specific organs like your skin, eyes, or brain. Vasculitis symptoms are very commonly observed symptoms such as fever, loss of appetite, weight loss, and fatigue.

The most common forms of Vasculitis are Giant cell arteritis, Polymyalgia rheumatica, Polyarteritis nodosa, and Granulomatosis with polyangiitis. Whereas, different types of Vasculitis are Large Vessel Vasculitis, Medium Vessel Vasculitis, and Small Vessel Vasculitis.

Vasculitis treatment depends on what’s causing your Vasculitis and which organs are affected. Corticosteroid medications, also known as steroids, are generally preferred to fight inflammation.

Find out more about the disease and recently developing strategies @ Vasculitis Pipeline Assessment

Vasculitis Pipeline Drugs

DrugCompanyPhaseMoARoA
AMB 301AmbuleroPreclinicalE-selectin stimulants; Gene transferenceParenteral
Research program:

Kidney Disorder

Therapeutics

VisterraPreclinicalNAParenteral
BDB 1Beijing Defengrei

Biotechnology

Phase I/IIComplement C5 inhibitors; Complement C5a inhibitorsIntravenous
VilobelimabInflaRxPhase IIComplement C5a inhibitorsIntravenous
GuselkumabJanssen BiotechPhase IIInterleukin-23 subunit p19 inhibitorsIntravenous/ Subcutaneous
SecukinumabNovartisPhase IIIIL17A protein inhibitorsSubcutaneous
UpadacitinibAbbViePhase IIIJanus kinase 1 inhibitorsOral

Learn more about the novel and emerging Vasculitis pipeline therapies @ Vasculitis Pipeline Analysis

Vasculitis Therapeutics Assessment

The Vasculitis Pipeline report proffers an integral view of the Vasculitis emerging novel therapies segmented by Stage, Product Type, Mechanism of Action, Route of Administration, and Molecule Type.

Scope of the Vasculitis Pipeline Report

  • Coverage: Global
  • Therapeutic Assessment By Vasculitis Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Vasculitis Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
  • Therapeutics AssessmentBy Vasculitis Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous
  • Therapeutics AssessmentBy Vasculitis Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules
  • Therapeutics AssessmentBy Vasculitis Therapies Mechanism of Action: Interleukin-23 subunit p19 inhibitors, Janus kinase 1 inhibitor, IL17A protein inhibitors, Complement C5a inhibitors, E-selectin stimulants, E-selectin stimulants, Gene transference, Immunomodulators, TYK2 kinase inhibitors, Antibody-dependent cell cytotoxicity, Apoptosis stimulants
  • Key Vasculitis Companies: CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and others.
  • Key Vasculitis Pipeline Therapies: AMB 301, Research program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others

Dive deep into rich insights for emerging drugs and pipeline assessment, visit @ Vasculitis Emerging Therapies

Table of Contents

1Introduction
2Executive Summary
3Vasculitis: Overview
4Pipeline Therapeutics
5Late Stage Products (Phase III)
5.1Secukinumab: Novartis
6Early Stage Products (Phase I/II)
6.1BDB 1: Beijing Defengrei Biotechnology
7Preclinical Stage Products
7.1AMB 301: Ambulero
8Discovery Stage Products
9Therapeutic Assessment
10Inactive Products
11Collaborations Licensing / Partnering / Funding
12Vasculitis - Unmet Needs
13Vasculitis - Market Drivers and Barriers
14Appendix
15About DelveInsight

For further information on the Vasculitis current pipeline therapeutics, reach out @ Vasculitis Ongoing Clinical Trials

Related Reports

Peripheral Vascular Interventions Market

Peripheral Vascular Interventions Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Peripheral Vascular Interventions companies.

Peripheral Vascular Clot Management Interventions Market

Peripheral Vascular Clot Management Interventions Market Insight, Competitive Landscape, and Market Forecast, 2026 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Peripheral Vascular Clot Management Interventions companies such as Boston Scientific Corporation, Penumbra Inc, Medtronic, Koninklijke Philips N.V., Edward Lifesciences Corporation, among others.

Choroidal Neovascularization Pipeline Insights

"Choroidal Neovascularization Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Choroidal Neovascularization market. A detailed picture of the Choroidal Neovascularization pipeline landscape is provided, which includes the disease overview, treatment guidelines, and key Choroidal Neovascularization companies involved such as Johnson & Johnson, Medtronic, Stryker, Terumo Corporation, Penumbra, Inc., Microport Scientific Corporation, Kaneka Corp, and others.

Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market

Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market was valued at USD 681.36 million in 2020, growing at a CAGR of 6.11% during the forecast period from 2021 to 2026 to reach USD 969.17 million by 2026. The report delivers an in-depth understanding of Neurovascular Thrombectomy Devices and the historical and forecasted Neurovascular Thrombectomy Devices market trends, market drivers, market barriers, and key Neurovascular Thrombectomy Devices companies involved such as Stryker, Penumbra, Vesalio, Acandis GmbH, Rapid Medical, Johnson & Johnson, Teleflex Incorporated, Medtronic, NeuroVasc Technologies, Inc., Perflow Medical, Edward LifeSciences Corporation, and many others.

Neurovascular Coiling Assist Devices Market

DelveInsight’s ‘Neurovascular Coiling Assist Devices Market Insights, Competitive Landscape and Market Forecast - 2025’ report delivers an in-depth understanding of Neurovascular Coiling Assist Devices and the historical and forecasted Neurovascular Coiling Assist Devices market trends, market drivers, market barriers, and key Neurovascular Coiling Assist Devices companies involved such as Acandis GmBH, BALT Extrusion, Johnson & Johnson (Cerenovus), Medtronic Plc, Stryker, Terumo (MicroVention), and others.

Peripheral Vascular Clot Management Interventions Market

DelveInsight’s ‘Peripheral Vascular Clot Management Interventions Market Insights, Competitive Landscape, and Market Forecast-2026’ report delivers an in-depth understanding of peripheral vascular clot management interventions and the historical and forecasted peripheral vascular clot management interventions market trends, market drivers, market barriers, and key Peripheral Vascular Clot Management Interventions companies involved such as Boston Scientific Corporation, Penumbra Inc, Medtronic, Koninklijke Philips N.V., Edward Lifesciences Corporation, Cardinal Health, Argon Medical Devices, Inc., Control Medical Technology, B. Braun Melsungen AG., Inari Medical, and others.

Nerve Monitoring Systems Market

Global Nerve Monitoring Systems Market was valued at USD 1.23 billion in 2020, growing at a CAGR of 4.17% during the forecast period from 2021 to 2026, to reach USD 1.72 billion by 2026. The report delivers an in-depth understanding of Nerve Monitoring Systems and the historical and forecasted Nerve Monitoring Systems market trends, market drivers, market barriers, and key Nerve Monitoring companies involved such as Medtronic PLC, Nihon Kohden Corporation, Natus Medical Incorporated, Innopsys Inc, Neurovision Medical Products, NeuroWave Systems Inc, Cadwell Industries, Dr. Langer Medical GmbH, Inomed Medizintechnik GmbH, Symmetry Surgical, Checkpoint Surgical Inc, and many others.

Vascular Access Devices Market

Global Vascular Access Devices Market was valued at USD 4.31 billion in 2020, growing at a CAGR of 6.64% during the forecast period from 2021 to 2026, to reach USD 6.13 billion by 2026. The report delivers an in-depth understanding of Vascular Access Devices and the historical and forecasted Vascular Access Devices market trends, market drivers, market barriers, and key Vascular Access Devices companies involved such as Becton, Dickinson, and Company, Teleflex Incorporated, Medtronic PLC, Zoll Medical Corporation, B Braun Melsungen AG, Prodimed, Amecath Medical Technologies, Terumo Medical Corporation, AngioDynamics, Edwards Lifesciences Corporation, C. R. Bard, Smiths Group PLC, Nipro Medical Corporation, and many others.

Neurovascular Catheters Devices Market

DelveInsight’s ‘Neurovascular Catheters Devices Market Insight, Competitive Landscape, and Market Forecast, 2026’ report delivers an in-depth understanding of Neurovascular Catheters Devices and the historical and forecasted Neurovascular Catheters Devices market trends. Neurovascular Catheters Devices market will be covered in-depth in the report comprising of company overview, financial overview, product overview and company share analysis of key players.

Browse Through Our Blog Posts

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us

Shruti Thakur

info@delveinsight.com

+1(919)321-6187

www.delveinsight.com

關注我們Facebook專頁
    相關新聞
      更多瀏覽